

## ESMO Sarcoma and GIST Conference 2016 Industry Satellite Symposium

### Potential for immunotherapy in soft tissue sarcoma

16 February, 2016 – Milan, Italy

H 18:20 - 19:20 - Level -1, Manzoni Room

## Overview

Although rare, Soft Tissue Sarcomas (STS) are complex tumors which we are only beginning to understand. STS is not a single type of tumor but rather encompasses a variety of tumors which arise from different tissues within the body. In the past decade, there has been increased recognition of the tremendous heterogeneity of STS, with now over 50 distinct subtypes recognized by the World Health Organization. Importantly, each subtype has unique disease biology, clinical behavior and response to therapy. Current treatment options for patients with STS are limited, in particular for those with locally-advanced, recurrent, or metastatic disease. Several aspects of STS disease biology suggest that there is strong rationale for immunotherapy, including the presence of chromosomal translocations which result in unique fusion proteins, high expression of cancer testis antigens, and to a lesser extent, the moderate frequency of genetic mutations. In addition, a naturally-occurring immune infiltrate has been reported for several STS subtypes. The currently available human data to support the efficacy of immunotherapy in STS, however, is still limited and the potential for immunotherapy in the treatment of STS is only beginning to be explored.

## Learning objectives

- Describe the molecular determinants of soft tissue sarcomas
- Illustrate the hypoxic microenvironment in soft tissue sarcomas and its biological consequences
- Analyze the possible strategies to target hypoxia in soft tissue sarcomas

## Target Audience


Surgeons, medical oncologists, radiologists, pathologists, radiotherapists with experience in the diagnosis and treatment of soft tissue sarcomas.

## Scientific Programme

- 18.20 Welcome & Opening
- 18.25 L1 Immune checkpoint targeting in cancer therapy
- 18.55 L2 Sarcoma immunotherapy: focus on checkpoint inhibitors
- 19.15 Concluding remarks
- 19.20 End of the symposium

## How to find the symposium

### Level -1 - Room Manzoni



**EXCEMED | Improving the patient's life through medical education**  
[www.excemed.org](http://www.excemed.org)

All EXCEMED programmes are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of EXCEMED. This programme is made possible thanks to an educational grant received from Merck KGaA, Darmstadt, Germany

